Clinical Trials Logo
  1. Home
  2. Non-small-cell Lung
  3. NCT05465733

First-line Replacement Maintenance of Envafolimab in Advanced NSCLC — NSCLC  

Non-Small-Cell Lung Clinical Trial

Official title:
A Prospective, Single-arm, Single-center Clinical Trial of Envafolimab as First-line Replacement Maintenance in Advanced NSCLC

Clinical Trial Summary

This study is a single-center, prospective, single-arm phase II clinical study. For newly-treated patients with advanced NSCLC with negative driver gene and positive PD-L1 expression, those patients who did not progress after 4-6 cycles of PD-1 or PD-1 combined with chemotherapy standard treatment, after signing the informed consent form, were screened to meet the criteria for inclusion and exclusion. Standard, will receive Envafolimab combined with chemotherapy/Envafolimab single-agent first-line maintenance therapy until disease progression, withdrawal of informed consent, initiation of other anti-tumor therapy, death, or other protocol-specified conditions that should be discontinued Circumstances, whichever occurs first.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05465733
Study type Interventional
Source First Affiliated Hospital Xi'an Jiaotong University
Contact Yu Yao, PhD
Phone 029-85324600
Email yaoyu123@xjtufh.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date August 1, 2022
Completion date June 30, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04362072 - Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer Phase 4
Not yet recruiting NCT03766490 - Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer N/A
Terminated NCT03626545 - Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy Phase 3
Not yet recruiting NCT03389256 - Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC Phase 2
Active, not recruiting NCT03952403 - A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 3
Recruiting NCT05261399 - Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment Phase 3
Completed NCT00034879 - Iressa Expanded Access Program (EAP) Phase 3
Active, not recruiting NCT03456063 - A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) Phase 3
Completed NCT00863746 - A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). Phase 3